MEDCL Stock Analysis: Medincell | PA
Biotechnology | PA, France | Market Cap: 893m EUR | 12M Return: 1.5% | FR0004065605 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.04M
Warnings
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MedinCell S.A. is a French clinical-stage and commercial biopharmaceutical company headquartered in Jacou, France, founded in 2003. It operates on a licensing business model, developing long-acting injectable formulations based on its proprietary BEPO technology platform. This platform enables sustained drug release, which in the biopharmaceutical sector typically aims to reduce dosing frequency and improve patient adherence compared with conventional oral or short-acting injectable therapies.
The companys first commercial product is UZEDY (mdc-IRM), approved for the treatment of schizophrenia and bipolar I disorder in adults. Its late-stage pipeline includes mdc-TJK, a subcutaneous injection for schizophrenia currently in NDA preparation, and mdc-CWM, a sustained-release celecoxib formulation in Phase III for post-operative pain management following total knee arthroplasty. Earlier-stage candidates target contraception (mdc-WWM) and malaria (mdc-STM), reflecting a diverse therapeutic pipeline across central nervous system, pain, womens health, and infectious diseases.
MedinCells growth strategy is anchored by strategic collaborations with major industry players, including AbbVie-covering six long-acting injectable therapeutic products-and IM4TB for the development of a long-acting injectable treatment for tuberculosis. These partnerships are typical of small-cap biotechnology firms (the companys market capitalization is approximately $1 billion), which often rely on licensing agreements and collaborations with larger pharmaceutical companies to fund development, leverage manufacturing scale, and access global commercialization channels.
- UZEDY schizophrenia launch ramps commercial revenue
- AbbVie partnership expands six long-acting injectable programs
- mdc-CWM Phase III pain data and mdc-TJK NDA progress
| Net Income: -31.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -12.28 > 1.0 |
| NWC/Revenue: 389.5% < 20% (prev 198.7%; Δ 190.8% < -1%) |
| CFO/TA -0.23 > 3% & CFO -25.1m > Net Income -31.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.9m) vs 12m ago 23.92% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 19.66% > 50% (prev 28.24%; Δ -8.57% > 0%) |
| Interest Coverage Ratio: -4.88 > 6 (EBIT TTM -32.1m / Interest Expense TTM 6.58m) |
| A: 0.70 (Total Current Assets 96.7m - Total Current Liabilities 20.7m) / Total Assets 108.1m |
| B: -0.29 (Retained Earnings -31.3m / Total Assets 108.1m) |
| C: -0.32 (EBIT TTM -32.1m / Avg Total Assets 99.3m) |
| D: 0.03 (Book Value of Equity 3.06m / Total Liabilities 105.0m) |
| Altman-Z'' = 1.53 = BB |
| DSRI: 1.84 (Receivables 4.51m/3.21m, Revenue 19.5m/25.5m) |
| GMI: 0.95 (GM 95.48% / 100.0%) |
| AQI: 1.16 (AQ_t 0.06 / AQ_t-1 0.05) |
| SGI: 0.76 (Revenue 19.5m / 25.5m) |
| TATA: -0.06 (NI -31.3m - CFO -25.1m) / TA 108.1m) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of October 10, 2026, the stock is trading at EUR 29.06 with a total of 675,207 shares traded. Over the past week, the price has changed by +30.90%, over one month by +31.97%, over three months by +4.38% and over the past year by +1.47%.
Current recommended Stop Loss: 26.70 (which is 8.1% or 1.9 ATR below the current price).
Medincell has no consensus analysts rating.
P/S = 36.7848
P/B = 265.4303
Revenue TTM = 19.5m EUR
EBIT TTM = -32.1m EUR
EBITDA TTM = -30.3m EUR
Long Term Debt = 52.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 3.30m EUR (from shortTermDebt, last quarter)
Debt = 59.8m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.39m
Net Debt = -677k EUR (calculated: Debt 59.8m - CCE 60.5m)
Enterprise Value = 892.3m EUR (893.0m + Debt 59.8m - CCE 60.5m)
Interest Coverage Ratio = -4.88 (Ebit TTM -32.1m / Interest Expense TTM 6.58m)
EV/FCF = -29.47x (Enterprise Value 892.3m / FCF TTM -30.3m)
FCF Yield = -3.39% (FCF TTM -30.3m / Enterprise Value 892.3m)
FCF Margin = -155.1% (FCF TTM -30.3m / Revenue TTM 19.5m)
Net Margin = -160.3% (Net Income TTM -31.3m / Revenue TTM 19.5m)
Gross Margin = unknown ((Revenue TTM 19.5m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 8.26 (Enterprise Value 892.3m / Total Assets 108.1m)
Interest Expense / Debt = 11.01% (Interest Expense 6.58m / Debt 59.8m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -24.1m (EBIT -32.1m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 4.01 (Total Current Assets 96.7m / Total Current Liabilities 24.1m)
Debt / Equity = 19.52 (Debt 59.8m / totalStockholderEquity, last quarter 3.06m)
Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -677k / EBITDA -30.3m)
Debt / FCF = 0.02 (negative FCF - burning cash) (Net Debt -677k / FCF TTM -30.3m)
Total Stockholder Equity = -24.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.52% (Net Income -31.3m / Total Assets 108.1m)
RoE = 127.7% (negative equity) (Net Income TTM -31.3m / Total Stockholder Equity -24.5m)
RoCE = -115.0% (out of range, set to none) (EBIT -32.1m / Capital Employed (Equity -24.5m + L.T.Debt 52.4m))
RoIC = -26.84% (negative operating profit) (NOPAT -24.1m / Invested Capital 89.7m)
WACC = 6.76% (E(893.0m)/V(952.8m) * Re(6.66%) + D(59.8m)/V(952.8m) * Rd(11.01%) * (1-Tc(0.25)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.28 | Cagr: 17.24%
[DCF] Fair Price = unknown (Cash Flow -30.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.14 | # QB: 0
Revenue Correlation: 81.26 | Revenue CAGR: 44.47% | SUE: -2.07 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-03-31): EPS=-0.48 | Chg30d=+3.76% | Revisions=+25% | GrowthEPS=+22.8% | GrowthRev=+22.5%
EPS next Year (2027-03-31): EPS=0.05 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+105.3% | GrowthRev=+65.2%
[Analyst] Revisions Ratio: +40% (up=2, down=0)